Drugs / Ozarelix
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01252693 | Nov 2010 → Sep 2014 | prostate cancer | Spectrum Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 2 | NCT00743184 | Dec 2008 → Jan 2010 | benign prostatic hyperplasia | Spectrum Pharmaceuticals, Inc | Terminated | No outcome recorded |
| Phase 2 | NCT00427219 | Jan 2007 → Feb 2008 | benign prostatic hyperplasia | Spectrum Pharmaceuticals, Inc | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ozarelix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00743184 ↗ |
| Known as | D-63153 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108312 ↗ |
| Action | Inhibit | “Gonadotropin-releasing hormone receptor antagonist” CHEMBL2108312 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2108312 ↗ |
| Route | Intramuscular | “administered IM” NCT00427219 ↗ |
| Target | GNRHR | “Gonadotropin-releasing hormone receptor antagonist” CHEMBL2108312 ↗ |